Indeed, 20% of ErbB2 breast cancer patients present primary resistance to ErbB2-targeting agents (e.g., trastuzumab, prastuzumab, lapatinib), and 70% of patients with ErbB2 metastatic cancer present acquired resistance [2]. This evidence concerns the gene ERBB2 and metastatic malignant neoplasm.